ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Memory Pharmaceuticals Initiates Phase 2a Trial Of MEM 3454 In Cognitive Impairment Associated With Schizophrenia
Memory
Pharmaceuticals Corp. (Nasdaq: MEMY) announced dosing of the first
subject in a randomized, double-blind, placebo-controlled Phase 2a clinical
trial of MEM 3454, the Company's lead nicotinic alpha-7 receptor partial
agonist, in cognitive impairment associated with schizophrenia (CIAS). The
trial is designed to assess the safety, tolerability and cognitive effects
of three doses of MEM 3454 in patients with CIAS. There are currently no
drugs approved to treat CIAS.
"Cognitive impairment is a major component of schizophrenia that
contributes to patients' inability to function," stated Stephen R. Murray,
M.D., Ph.D., Chief Medical Officer of Memory Pharmaceuticals. "There is a
strong rationale supporting the utility of MEM 3454 in CIAS, including the
efficacy findings from our recently completed positive Phase 2a clinical
trial of MEM 3454 in Alzheimer's disease. Given these findings, we are
excited to assess the potential of MEM 3454 to improve cognitive
impairments experienced by patients with schizophrenia. We currently expect
to complete this trial in the fourth quarter of 2008."
The trial will enroll approximately 160 patients with stable
schizophrenia who are receiving atypical antipsychotic therapy. Subjects
will be randomized to receive 5 mg, 15 mg or 50 mg of MEM 3454 or placebo
once daily for a period of eight weeks. The primary objective of the trial
is to assess the effectiveness of MEM 3454 in CIAS using the MATRICS
Consensus Cognitive Battery (MCCB). Secondary objectives include measures
of other symptoms of schizophrenia and functional capacity.
Roche has an option to secure a worldwide, exclusive license to develop
and commercialize MEM 3454 upon the fulfillment of certain predefined
events, including the recently completed Phase 2a trial of MEM 3454 in
Alzheimer's disease. Roche is obligated to make a milestone payment to
Memory Pharmaceuticals at the time this option is exercised. In June 2007,
Memory Pharmaceuticals expanded its nicotinic alpha-7 receptor agonist
agreement with Roche to support this Phase 2a trial of MEM 3454 in CIAS.
The expanded agreement provides that Roche would have to make an additional
milestone payment upon completion of the Phase 2a CIAS trial to maintain
its license to MEM 3454. The additional milestone payment, if made, is
expected to cover the expenses related to the Phase 2a CIAS trial of MEM
3454.
MEM 3454 is a partial agonist of the nicotinic alpha-7 receptor, a
highly specialized receptor found in the central nervous system. Compounds
acting on this receptor could be beneficial in the treatment of Alzheimer's
disease and schizophrenia, as well as other psychiatric and neurological
disorders. MEM 3454 is the Company's lead drug candidate from its nicotinic
alpha-7 agonist program.
About CIAS
Cognitive impairment is recognized as a major component of
schizophrenia. The condition is characterized by a reduction in patients'
sensory-gating abilities and working and verbal memory, which impacts the
patient's ability to function normally. Although there are drugs approved
to treat the positive and negative symptoms associated with schizophrenia,
there are no currently available treatments that address the cognitive
deficits associated with the disorder.
About the Company
Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused
on developing innovative drugs for the treatment of debilitating CNS
disorders such as Alzheimer's disease, schizophrenia and depression. For
additional information, please visit our website at
http://www.memorypharma.com.
Safe Harbor Statement
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks and uncertainties. All statements, other than statements
of historical facts, regarding management's expectations, beliefs, goals,
plans or Memory Pharmaceuticals' prospects, future financial position,
future revenues and projected costs should be considered forward-looking.
Readers are cautioned that actual results may differ materially from
projections or estimates due to a variety of important factors, including
the risks and uncertainties associated with: obtaining additional financing
to support Memory Pharmaceuticals' R&D and clinical activities and
operations; the outcome of clinical trials of Memory Pharmaceuticals' drug
candidates and whether they demonstrate these candidates' safety and
effectiveness; obtaining regulatory approvals to conduct clinical trials
and to commercialize Memory Pharmaceuticals' drug candidates; Memory
Pharmaceuticals' ability to enter into and maintain collaborations with
third parties for its drug development programs; Memory Pharmaceuticals'
dependence on its collaborations and its license relationships; achieving
milestones under Memory Pharmaceuticals' collaborations; Memory
Pharmaceuticals' dependence on preclinical and clinical investigators,
preclinical and clinical research organizations, manufacturers and
consultants; and protecting the intellectual property developed by or
licensed to Memory Pharmaceuticals. These and other risks are described in
greater detail in Memory Pharmaceuticals' filings with the Securities and
Exchange Commission. Memory Pharmaceuticals may not actually achieve the
goals or plans described in its forward-looking statements, and investors
should not place undue reliance on these statements. Memory Pharmaceuticals
disclaims any intent or obligation to update any forward-looking statements
as a result of developments occurring after the date of this press release.
Memory Pharmaceuticals Corp.
http://www.memorypharma.com
Memory Pharmaceuticals iniþiazã Faza 2a proces al MEM În 3454 cognitive Deprecierea Asociat cu schizofrenie - Memory Pharmaceuticals Initiates Phase 2a Trial Of MEM 3454 In Cognitive Impairment Associated With Schizophrenia - articole medicale engleza - startsanatate